The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

mRNA Therapeutics and Vaccines Market, 2020-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    January 2021

  • Pages
    253

  • View Count
    7567

Example Insights

mRNA-Therapeutics-and-Vaccines-Context mRNA-Therapeutics-and-Vaccines-Development-Pipeline mRNA-Therapeutics-and-Vaccines-Grid-Analysis
mRNA-Therapeutics-and-Vaccines-Competitiveness-Analysis mRNA-Therapeutics-and-Vaccines-Key-Applicants mRNA-Therapeutics-and-Vaccines-Type-of-Partnership
mRNA-Therapeutics-and-Vaccines-Funding-and-Investments mRNA-Therapeutics-and-Vaccines-Routes-of-Administration  

 

Overview

Medical researchers first began evaluating mRNA as a therapeutic modality in the 1990s. The clinical use of mRNA is presently being evaluated in both therapeutic (protein replacement therapies, and as an alternative to classical gene therapies) and preventive (mRNA vaccines) roles. There are over 65 mRNA therapeutics and more than 85 vaccines currently in the development pipeline. As a biomolecule, mRNA is well tolerated in vivo, and (depending on the encoded protein) is capable of inducing humoral and cell-mediated immune responses. Moreover, using this approach, researchers have demonstrated that it is possible to deliver adequate amounts of tumor antigens (bearing patient-specific molecular signatures), and provide the necessary costimulatory signals to mount an effective anticancer immune response. As indicated earlier, mRNA-based interventions are also being evaluated as protein replacement therapies and alternatives to classical gene therapies; however, research on the aforementioned modalities is still in its infancy, with several potential leads in the preclinical stages. Such therapies are predominantly being developed for treating rare disorders. On the other hand, using mRNA, it is possible to develop both personalized (for various cancer) and general-use vaccines (for infectious diseases). Interestingly, mRNA vaccines have shorter development and manufacturing timelines, compared to their traditional counterparts. In fact, Pfizer and BioNtech’s recently approved vaccine (BNT-162) and Moderna’s late phase candidate (mRNA-1273) against the novel coronavirus strain, are both mRNA-based preventive solutions.

Despite the potential benefits, there are, however, several challenges that limit the use of mRNA as a therapeutic. One of the major concerns is related to the short cytoplasmic half-life of the molecule, which compromises its efficacy as a therapeutic / vaccine. Other known setbacks of using mRNA as a therapy include its large size and inherent antigenicity, which complicate therapy administration and immune tolerance, respectively. Over the years, manipulation of the chemical structure of mRNA has enabled medical researchers and therapy developers to address some of the aforementioned challenges. Similarly, with regards to therapy delivery, lipoplexes and lipid-based nanoparticles are now preferred vehicles (among other contemporary nucleic acid delivery methods) for the targeted, intracellular delivery of therapeutic mRNA. However, companies (mostly startups and small firms) engaged in this field still claim to be in pursuit of better drug delivery strategies. In the last five years alone, close to USD 8 billion has been invested into companies that are engaged in developing mRNA-based therapeutics and vaccines; a significant proportion of the capital has come from public sector investors / state-backed institutes. Further, over the last few years, there has been noticeable consolidation, with stakeholders entering into strategic partnerships to support ongoing R&D initiatives. In the foreseen future, as more mRNA-based therapeutic / vaccine leads demonstrate proof-of-concept, enter into clinical testing and are eventually marketed, the opportunity for stakeholders engaged in this niche industry segment is anticipated to witness substantial growth.

Scope of the Report

The “mRNA Therapeutics and Vaccines Market, 2020-2030” report features an extensive study of the current market landscape and future potential of the players engaged in the development of mRNA-based therapeutics and vaccines for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of mRNA therapeutics and vaccines, along with information on type of product candidate, phase of development, type of development program, type of delivery vehicle, target disease indication, target therapeutic area and route of administration. It also includes details related to year of establishment, company size (in terms of number of employees) and location of headquarters of the drug developers. Further, it presents an elaborate analysis of the contemporary trends, presented using two schematic representations, including [A] logo landscape, highlighting the distribution of drug developers based on company size and location of their headquarters, and [B] grid analysis, presenting the distribution of drugs based on target disease indication, type of development program and type of candidate. It also provides a detailed analysis of key therapeutic areas, such as oncological disorders and infectious diseases, for which mRNA-based therapeutics and vaccines are being developed.
  • A competitiveness analysis of key players engaged in this domain. The analysis is presented in the form of spider web representations, which take into consideration several important parameters, such as number of early stage candidates, number of late stage candidates, number of deals signed, amount raised through funding, company size (in terms of number of employees) and years of experience in the industry. 
  • Detailed profiles of drug candidates that are in advanced stages of development. Each profile features an overview of the drug and respective developer, details related to type of candidate, route of administration, phase of development, target disease indication and therapeutic area, mechanism of action, technology used, and recent developments (including information of partnerships, clinical trials and results and special review designations awarded).
  • An analysis of the completed, ongoing and planned clinical studies for mRNA therapeutics and vaccines. The trials considered in the analysis were analyzed on the basis of various relevant parameters, such as trial registration year, trial recruitment status, number of patients enrolled, study design, target patient segment, trial focus area, target therapeutic area, geographical location of trials and leading organizations.
  • An in-depth analysis of the various patents that have been filed / granted related to mRNA delivery technologies / methods, since 2017. The analysis also highlights the key parameters associated with the patents, including information on patent application year, patent publication year, geographical location / patent jurisdiction, IPCR symbols, emerging focus areas and leading players. In addition, it includes detailed patent benchmarking analysis based on leading players. Further, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • An analysis of the partnerships that have been inked by stakeholders engaged in the development of mRNA-based therapeutics and vaccines, during the period 2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements, and other relevant types of deals. 
  • An analysis of the investments made, including award / grant, seed financing, venture capital financing, debt financing and others, in companies that are engaged in the development of mRNA-based therapeutics and vaccines
  • A discussion on the affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under an elaborate SWOT framework. It also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.  

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the mRNA therapeutics and vaccines market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] key therapeutic areas (infectious diseases and oncological disorders), [B] route of administration (intravenous and intramuscular) and [D] key geographical regions (North America, Europe, Asia Pacific, MENA and LATAM regions). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Key Questions Answered

  • Who are the leading players engaged in the development of mRNA therapeutics and vaccines?
  • Which key clinical conditions can be treated by mRNA drugs?
  • What are the investment trends in this industry?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • Which regions have emerged as the key hubs for conducting clinical studies focused on mRNA drugs?
  • How has the intellectual property landscape in this market evolved over the years?
  • Which factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the mRNA therapeutics and vaccines market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general overview of mRNA therapeutics and vaccines, including information on the advantages of these novel biological entities and their historical evolution. The chapter lays emphasis on the application areas of mRNA drugs. Further, it includes information on delivery routes and vehicles for the transfer of mRNA drugs in the body. It also includes a discussion on the various challenges associated with their therapeutic use.

Chapter 4 presents a detailed assessment of the current market landscape of mRNA therapeutics and vaccines, along with information on type of product candidate, phase of development, type of development program, type of delivery vehicle, target disease indication, target therapeutic area and route of administration. It also includes details related to year of establishment, company size (in terms of number of employees) and location of headquarters of the drug developers. Further, it presents an elaborate analysis of the contemporary trends, presented using two schematic representations, including [A] logo landscape, highlighting the distribution of drug developers based on company size and location of their headquarters, and [B] grid analysis, presenting the distribution of drugs based on target disease indication, type of development program and type of candidate. It also provides an in-depth analysis of key therapeutic areas, such as oncological disorders, infectious diseases for which mRNA based therapeutics and vaccines are being developed.

Chapter 5 includes a competitiveness analysis of key players engaged in this domain. The analysis is presented in the form of spider web representations, which take into consideration several important parameters, such as number of early stage candidates, number of late stage candidates, number of deals signed, amount raised through funding, company size (in terms of number of employees) and years of experience in the industry. 

Chapter 6 consists of detailed profiles of drug candidates that are in advanced stages of development. Each profile features an overview of the drug and respective developer, details related to type of candidate, route of administration, phase of development, target disease indication and therapeutic area, mechanism of action, technology used, and recent developments (including information of partnerships, clinical trials and results and special review designations awarded).

Chapter 7 features an analysis of the completed, ongoing and planned clinical studies for mRNA therapeutics and vaccines. The trials considered in the analysis were analyzed on the basis of various relevant parameters, such as trial registration year, trial recruitment status, number of patients enrolled, study design, target patient segment, trial focus area, target therapeutic area, geographical location of trials and leading organizations.

Chapter 8 An in-depth analysis of the various patents that have been filed / granted related to mRNA delivery technologies / methods, since 2017. The analysis also highlights the key parameters associated with the patents, including information on patent application year, patent publication year, geographical location / patent jurisdiction, IPCR symbols, emerging focus areas and leading players. In addition, it includes detailed patent benchmarking analysis based on leading players. Further, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 9 includes detailed assessment of the partnerships that have been inked by stakeholders engaged in the development of mRNA-based therapeutics and vaccines, during the period 2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements, and other relevant types of deals. 

Chapter 10 provides insights on the investments made, including award / grant, seed financing, venture capital financing, debt financing and others, in companies that are engaged in the development of mRNA-based therapeutics and vaccines.

Chapter 11 presents a detailed analysis of the current and forecasted opportunity across [A] key therapeutic areas (infectious diseases and oncological disorders), [B] route of administration (intravenous and intramuscular) and [D] key geographical regions (North America, Europe, Asia Pacific, MENA and LATAM regions). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter 12 includes a discussion on the affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under an elaborate SWOT framework. It also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.  

Chapter 13 is a summary of the overall report. It includes key takeaways related to research and analysis from the report in an infographic format

Chapter 14 presents an insightful discussion on the views presented by various industry experts present across the globe, on YouTube. The summary of insights provided by each expert is discussed across focus area, current industry status / challenges and future outlook.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides list of companies and organizations highlighted in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. mRNA Therapeutics
3.2.1. Advantages of mRNA Therapeutics
3.2.2. Applications of mRNA Therapeutics
3.3. mRNA Vaccines
3.3.1. Advantages of mRNA Vaccines
3.3.2. Applications of mRNA Vaccines
3.4. Delivery Routes for mRNA Therapeutics and Vaccines
3.5. mRNA Delivery Strategies
3.6. Challenges Associated with mRNA Therapeutics and Vaccines

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. mRNA Therapeutics and Vaccines: Development Pipeline
4.2.1. Analysis by Type of Product Candidate
4.2.2. Analysis by Phase of Development
4.3.3. Analysis by Type of Development Program
4.2.4. Analysis by Type of Delivery Vehicle
4.2.5. Analysis by Disease Indication 
4.2.6. Analysis by Target Therapeutic Area
4.2.7. Analysis by Route of Administration
4.2.8. Key mRNA-based Technology Platforms
4.2.9 Key Players
4.2.10 Clinical Stage Candidates: Sales Rights

4.3. mRNA Therapeutics and Vaccines: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.4 Logo Landscape: Analysis by Company Size and Location of Headquarters
4.5 Grid Analysis by Disease Indication, Type of Program and Type of Candidate

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Parameters and Methodology
5.3. Spider Web Analysis

6. DRUG PROFILES
6.1. Chapter Overview
6.2. mRNA-1273 (Moderna Therapeutics)
6.3. BNT162 (BioNTech)
6.4. AZD8601 (Moderna Therapeutics / AstraZeneca)
6.5. BNT122 (BioNTech)
6.6. COVID-19 (CureVac)
6.7. mRNA-1647 (Moderna Therapeutics)
6.8. mRNA-4157 (Moderna Therapeutics)
6.9. mRNA-2416 (Moderna Therapeutics)
6.10. mRNA-3927 (Moderna Therapeutics)
6.11. MRT5005 (Translate Bio)

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. mRNA Therapeutics and Vaccines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Registration Year and Trial Recruitment Status
7.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.4. Analysis by Study Design
7.3.5. Analysis by Patient Segment
7.3.6. Analysis by Trial Focus Area
7.3.7. Analysis by Therapeutic Area
7.3.8. Geographical Analysis by Number of Clinical Trials
7.3.9. Geographical Analysis by Trial Registration Year and Enrolled Patient Population
7.3.10. Leading Organizations: Analysis by Number of Registered Trials

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. mRNA Technologies / Methods: Patent Analysis
8.3.1. Analysis by Application Year
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Geographical Location
8.3.4. Analysis by IPCR Symbols
8.3.5. Analysis by Emerging Focus Areas
8.3.6. Leading Players: Analysis by Number of Patents
8.3.7. mRNA Technologies / Methods: Patent Benchmarking Analysis
8.3.7.1 Analysis by Key Patent Characteristics
8.3.8 mRNA Technologies / Methods: Patent Valuation Analysis

9. RECENT PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnership Models

9.3. mRNA Therapeutics and Vaccines: Recent Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Most Active Players: Analysis by Number of Partnerships
9.3.5. Regional Analysis

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. mRNA Therapeutics and Vaccines: Funding and Investment Analysis
10.3.1. Analysis by Cumulative Funding Instances, 2010-2020
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Year and Type of Funding
10.3.5. Regional Analysis by Amount Invested
10.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount Raised
10.3.7. Key Investors: Analysis by Number of Funding Instances

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Scope and Limitations
11.3. Key Assumptions and Forecast Methodology
11.4. Overall mRNA Therapeutics and Vaccines Market, 2020-2030
11.4.1. mRNA Therapeutics and Vaccines Market: Analysis by Key Therapeutic Areas
11.4.2. mRNA Therapeutics and Vaccines Market: Analysis by Route of Administration
11.4.3. mRNA Therapeutics and Vaccines Market: Analysis by Geography
11.5. mRNA Therapeutics and Vaccines Market: Product-wise Sales Forecasts

11.5.1. mRNA-1273
11.5.1.1. Target Patient Population
11.5.1.2. Sales Forecast

11.5.2. BNT-162
11.5.2.1. Target Patient Population
11.5.2.2. Sales Forecast

11.5.3. AZD8601
11.5.3.1. Target Patient Population
11.5.3.2. Sales Forecast

11.5.4. COVID-19
11.5.4.1. Target Patient Population
11.5.4.2. Sales Forecast

11.5.5. mRNA-1647
11.5.5.1. Target Patient Population
11.5.5.2. Sales Forecast

11.5.6. mRNA-4157
11.5.6.1. Target Patient Population
11.5.6.2. Sales Forecast

11.5.7. ARCT-021
11.5.7.1. Target Patient Population
11.5.7.2. Sales Forecast

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2 Comparison of SWOT Factors
12.2.1 Concluding Remarks

13. CONCLUSION
13.1. Chapter Overview
13.2. Key Takeaways

14. mRNA THERAPEUTICS AND VACCINES: EXPERT INSIGHTS
14.1. Chapter Overview
14.2. Industry Experts
14.2.1. Stéphane Bancel, President / Founding Chief Executive Officer (Moderna)
14.2.2. Ugur Sahin, Chief Executive Officer / Co-Founder (BioNTech)
14.2.3. Patrick Baumhof, Vice President Formulation and Delivery CureVac
14.2.4. Anna Collén, Project Leader (AstraZeneca)

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 mRNA Therapeutics and Vaccines: Historical Timeline
Figure 3.2 Applications of mRNA Therapeutics
Figure 3.3 Delivery Routes for mRNA
Figure 4.1 mRNA Therapeutics and Vaccines: Distribution by Type of Product Candidate
Figure 4.2 mRNA Therapeutics and Vaccines: Distribution by Phase of Development
Figure 4.3 mRNA Therapeutics and Vaccines: Distribution by Type of Development Program
Figure 4.4 mRNA Therapeutics and Vaccines: Distribution by Type of Delivery Vehicle
Figure 4.5 mRNA Therapeutics and Vaccines: Distribution by Type of Disease Indication
Figure 4.6 mRNA Therapeutics and Vaccines: Distribution by Target Therapeutic Area
Figure 4.7 mRNA Therapeutics and Vaccines: Distribution by Route of Administration
Figure 4.8 mRNA Therapeutics and Vaccines: Key Players
Figure 4.9 mRNA Therapeutics and Vaccines: Distribution by Year of Establishment
Figure 4.10 mRNA Therapeutics and Vaccines: Distribution by Company Size
Figure 4.11 mRNA Therapeutics and Vaccines: Distribution by Location of Headquarters
Figure 4.12 Logo Landscape: Distribution by Company Size and Location of Headquarters
Figure 4.13 Grid Representation: Distribution by Disease Indication, Type of Program and Type of Product Candidate
Figure 5.1 Company Competitiveness Analysis: Heat Map Representation
Figure 5.2 Spider Web Analysis: Benchmarking of Top Players
Figure 7.1 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2004- 2020 (Till September)
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, 2004-2020 (Till September)
Figure 7.5 Clinical Trial Analysis: Distribution by Study Design
Figure 7.6 Clinical Trial Analysis: Distribution by Patient Segment
Figure 7.7 Clinical Trial Analysis: Geographical Distribution of Clinical Trials
Figure 7.8 Clinical Trial Analysis: Focus Areas
Figure 7.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 7.8 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.9 Clinical Trial Analysis: Leading Organizations, In Terms of Number of Trials
Figure 7.10 Clinical Trial Analysis: Distribution by Focus Areas
Figure 7.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.12 Clinical Trial Analysis: Distribution by Type of Oncological Disorder
Figure 7.13 Clinical Trial Analysis: Distribution by Type of Infectious Disease
Figure 7.14 Clinical Trial Analysis: Distribution by Type of Genetic Disorder
Figure 8.1 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Type of Patent
Figure 8.2 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Application Year, 2017-2020 (till September)
Figure 8.3 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Publication Year
Figure 8.4 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Geographical Location
Figure 8.5 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by IPCR Symbols
Figure 8.6 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Focus Area
Figure 8.7 Patent Portfolio of mRNA Delivery Technologies / Methods: Leading Industry Players
Figure 8.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.9 mRNA Delivery Technologies / Methods, Patent Portfolio: Benchmarking by Patent Characteristics
Figure 8.10 mRNA Delivery Technologies / Methods, Patent Portfolio: Distribution by Age of Patents
Figure 8.11 Patent Portfolio of mRNA Delivery Technologies / Methods: Patent Valuation
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.4 Most Active Players: Distribution by Number of Partnerships
Figure 9.5 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 9.6 World Map Representation: Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investments: Cumulative Year-wise Trend, 2010-2020
Figure 10.2 Funding and Investments: Distribution of Amount Invested by Year and Number of Instances, 2010 - 2020 (USD Million)
Figure 10.3 Funding and Investments: Distribution of Instances by Type of Funding, 2012-2020 (USD Million)
Figure 10.4 Funding and Investments: Distribution by Year and Type of Funding, 2010-2020
Figure 10.5 Funding and Investments: Distribution of Instances by Total Amount Invested (USD Million) and Type of Funding, 2016 -2020
Figure 10.6 Funding and Investments: Most Active Players, 2010-2020 (USD Million)
Figure 10.7 Key Investors: Distribution by Number of Funding Instances and Amount Invested (USD Million)
Figure 10.8 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 11.1 Global mRNA Therapeutics and Vaccines Market, 2020-2030 (USD Million)
Figure 11.2 mRNA Therapeutics and Vaccines Market: Distribution by Key Therapeutic Areas, 2020, 2025 and 2030
Figure 11.3 mRNA Therapeutics and Vaccines Market: Distribution by Route of Administration, 2020, 2025 and 2030
Figure 11.4 mRNA Therapeutics and Vaccines Market: Distribution by Geography, 2020, 2025 and 2030
Figure 11.5 mRNA-1273 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.6 BNT-162 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.7 AZD8601 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.8 COVID-19 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.9 mRNA-1647 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.10 mRNA-4157 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.11 ARCT-021 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 12.1 mRNA Therapeutics and Vaccines Market: SWOT Factors
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1 Concluding Remarks: Current Market Landscape
Figure 13.2 Concluding Remarks: Funding and Investments
Figure 13.3 Concluding Remarks: Partnerships and Collaborations
Figure 13.4 Concluding Remarks: Patent Portfolio
Figure 13.5 Concluding Remarks: Clinical Trials
Figure 13.5 Concluding Remarks: Population Coverage
Figure 13.6 Concluding Remarks: Market Forecast

List Of Tables 

Table 4.1 mRNA Therapeutics and Vaccines: Development Pipeline
Table 4.2 mRNA Therapeutics and Vaccines: List of Drug Candidates (Information on Type of Product Candidate, Phase of Development, Type of Development Program and Type of Delivery Vehicle)
Table 4.3 mRNA Therapeutics and Vaccines: List of Drug Candidates (Information on Target Gene, Disease Indication, Target Therapeutic Area and Route of Administration)
Table 4.4 mRNA Therapeutics and Vaccines: List of Developers (Information on Year of Establishment, Company Size, Location of Headquarters and Number of Drug Candidates)
Table 4.5 List of Key mRNA-based Technology Platforms
Table 4.6 Clinical Stage Candidates: Information on Sales Rights
Table 6.1 mRNA Therapeutics and Vaccines: List of Drug Candidates Profiled
Table 6.2 Drug Profile: mRNA-1273
Table 6.3 Drug Profile: BNT162
Table 6.4 Drug Profile: AZD8601
Table 6.5 Drug Profile: BNT122
Table 6.6 Drug Profile: COVID-19
Table 6.7 Drug Profile: mRNA-1647
Table 6.8 Drug Profile: mRNA-4157
Table 6.9 Drug Profile: mRNA-3927
Table 6.10 Drug Profile: mRNA-2416
Table 6.11 Drug Profile: MRT5005
Table 8.1 Patent Portfolio of mRNA Delivery Technologies / Methods: ICPR Classification Symbol Definitions
Table 8.2 Patent Portfolio of mRNA Delivery Technologies / Methods: Most Popular ICPR Classification Symbols
Table 8.3 Patent Portfolio of mRNA Delivery Technologies / Methods: List of Top IPCR Classifications
Table 8.4 Patent Portfolio of mRNA Delivery Technologies / Methods: Summary of Benchmarking Analysis
Table 8.5 mRNA Delivery Technologies / Methods, Patent Portfolio: Categorizations based on Weighted Valuation Scores
Table 9.1 mRNA Therapeutics and Vaccines: List of Partnerships and Collaborations
Table 10.1 mRNA Therapeutics and Vaccines: List of Funding and Investments
Table 14.1 Moderna: Company Snapshot
Table 14.2 BioNTech: Company Snapshot
Table 14.3 CureVac: Company Snapshot
Table 14.4 AstraZeneca: Company Snapshot
Table 15.1 mRNA Therapeutics and Vaccines: Distribution by Type of Product Candidate
Table 15.2 mRNA Therapeutics and Vaccines: Distribution by Phase of Development
Table 15.3 mRNA Therapeutics and Vaccines: Distribution by Type of Development Program
Table 15.4 mRNA Therapeutics and Vaccines: Distribution by Type of Delivery Vehicle
Table 15.5 mRNA Therapeutics and Vaccines: Distribution by Type of Disease Indication
Table 15.6 mRNA Therapeutics and Vaccines: Distribution by Target Therapeutic Area
Table 15.7 mRNA Therapeutics and Vaccines: Distribution by Route of Administration
Table 15.8 mRNA Therapeutics and Vaccines: Key Players
Table 15.9 mRNA Therapeutics and Vaccines: Distribution by Year of Establishment
Table 15.10 mRNA Therapeutics and Vaccines: Distribution by Company Size
Table 15.11 mRNA Therapeutics and Vaccines: Distribution by Location of Headquarters
Table 15.12 Logo Landscape: Distribution by Company Size and Location of Headquarters
Table 15.13 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 15.14 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2004- 2020 (Till September)
Table 15.15 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Table 15.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, 2004-2020 (Till September)
Table 15.17 Clinical Trial Analysis: Distribution by Study Design
Table 15.18 Clinical Trial Analysis: Distribution by Patient Segment
Table 15.19 Clinical Trial Analysis: Geographical Distribution of Clinical Trials
Table 15.20 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 15.21 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Enrolled Patient Population
Table 15.22 Clinical Trial Analysis: Leading Organizations, In Terms of Number of Trials
Table 15.23 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 15.24 Clinical Trial Analysis: Distribution by Type of Oncological Disorder
Table 15.25 Clinical Trial Analysis: Distribution by Type of Infectious Disease
Table 15.26 Clinical Trial Analysis: Distribution by Type of Genetic Disorder
Table 15.27 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Type of Patent
Table 15.28 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Application Year, 2017-2020 (till September)
Table 15.29 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Publication Year
Table 15.30 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by Geographical Location
Table 15.31 Patent Portfolio of mRNA Delivery Technologies / Methods: Distribution by IPCR Symbols
Table 15.32 Patent Portfolio of mRNA Delivery Technologies / Methods: Leading Industry Players
Table 15.33 Leading Non-Industry Players: Distribution by Number of Patents
Table 15.34 mRNA Delivery Technologies / Methods, Patent Portfolio: Distribution by Age of Patents
Table 15.35 Patent Portfolio of mRNA Delivery Technologies / Methods: Valuation Analysis
Table 15.36 Partnerships and Collaborations: Distribution by Year of Partnership
Table 15.37 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.38 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 15.39 Most Active Players: Distribution by Number of Partnerships
Table 15.40 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 15.41 World Map Representation: Intercontinental and Intracontinental Agreements
Table 15.42 Funding and Investments: Cumulative Year-wise Trend, 2010-2020
Table 15.43 Funding and Investments: Distribution of Amount Invested by Year and Number of Instances, 2010 - 2020 (USD Million)
Table 15.44 Funding and Investments: Distribution of Instances by Type of Funding, 2012-2020 (USD Million)
Table 15.45 Funding and Investments: Distribution by Year and Type of Funding, 2010-2020
Table 15.46 Funding and Investments: Distribution of Instances by Total Amount Invested (USD Million) and Type of Funding, 2016 -2020
Table 15.47 Funding and Investments: Most Active Players, 2010-2020 (USD Million)
Table 15.48 Key Investors: Distribution by Number of Funding Instances and Amount Invested (USD Million)
Table 15.49 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 15.50 Global mRNA Therapeutics and Vaccines Market: Base, Conservative and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.51 mRNA Therapeutics and Vaccines Market: Distribution by Key Therapeutic Areas: Base, Conservative and Optimistic Scenario, 2020, 2025 and 2030 (USD Million)
Table 15.52 mRNA Therapeutics and Vaccines Market: Base, Conservative and Optimistic Scenario, Distribution by Route of Administration, 2020, 2025 and 2030 (USD Million)
Table 15.53 mRNA Therapeutics and Vaccines Market: Distribution by Geography, Base, Conservative and Optimistic Scenario, 2020, 2025 and 2030 (USD Million)
Table 15.54 mRNA-1273 Sales Forecast (Till 2030): Base, Conservative and Optimistic Scenario (USD Million)
Table 15.55 BNT-162 Sales Forecast (Till 2030): Base, Conservative and Optimistic Scenario (USD Million)
Table 15.56 AZD8601 Sales Forecast (Till 2030): Base, Conservative and Optimistic Scenario (USD Million)
Table 15.57 COVID-19 Sales Forecast (Till 2030): Base, Conservative and Optimistic Scenario (USD Million)
Table 15.58 mRNA-1647 Sales Forecast (Till 2030): Base, Conservative and Optimistic Scenario (USD Million)
Table 15.59 mRNA-4157 Sales Forecast (Till 2030): Base, Conservative and Optimistic Scenario (USD Million)
Table 15.60 ARCT-021 Sales Forecast (Till 2030): Base, Conservative and Optimistic Scenario (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. Arcturus Therapeutics
  2. Shanghai Bendao Gene Technology
  3. BIOCAD
  4. BioNTech
  5. CanSinoBIO
  6. Chimeron Bio
  7. CureVac
  8. Daiichi Sankyo
  9. Elixirgen Therapeutics
  10. eTheRNA
  11. ethris
  12. Gennova Biopharmaceuticals
  13. GreenLight Biosciences
  14. HDT Bio
  15. Kernal Biologics
  16. Mercurna
  17. Moderna
  18. Pantherna Therapeutics
  19. Providence Therapeutics
  20. ReCode Therapeutics
  21. Rejuvenation Technologies
  22. RNACure Biopharma
  23. RNAimmune
  24. Stemirna Therapeutics
  25. Tiba Biotech
  26. Translate Bio
  27. Versameb
  28. Walvax Biotechnology
  29. Ziphius Vaccines
  30. Neurimmune
  31. AstraZeneca
  32. University of Münster
  33. 20Med Therapeutics
  34. Centro Nacional de Investigaciones Cardiovasculares (CNIC)
  35. cmRNAbone
  36. Alexion Pharmaceuticals
  37. Karolinska Institutet
  38. Merck
  39. PPD
  40. Vertex Pharmaceuticals
  41. Lonza
  42. Catalent
  43. LABORATORIOS FARMACEUTICOS ROVI
  44. Amazon Web Services
  45. Chiesi Farmaceutici 
  46. Institut Pasteur
  47. United Kingdom Government
  48. Takeda Pharmaceuticals
  49. Qatar Government
  50. Frame Therapeutics
  51. Mymetics
  52. Image Analysis Group (IAG)
  53. Recipharm
  54. Johnson & Johnson Innovation
  55. Alcobra Pharmaceuticals
  56. Ultragenyx Pharmaceutical
  57. Janssen Pharmaceuticals
  58. Precision NanoSystems
  59. Duke-NUS Medical School
  60. European Union
  61. GlaxoSmithKline
  62. Coalition for Epidemic Preparedness Innovations (CEPI)
  63. Genmab 
  64. Yale University
  65. Harvard Medical School
  66. Eli Lilly
  67. Bill & Melinda Gates Foundation
  68. Boehringer Ingelheim
  69. Cancer Research Institute
  70. Acuitas Therapeutics
  71. Sanofi 
  72. Albany Molecular Research
  73. Shire
  74. Shanghai East Hospital
  75. National Institute on Aging (NIA)
  76. Astellas Innovation Management
  77. PROVIREX Genome Editing Therapies
  78. Helmholtz-Zentrum Geesthacht
  79. Fudan University
  80. Körber
  81. Beijing Institute of Biotechnology
  82. Genentech
  83. Bayer
  84. Pfizer
  85. Genevant Sciences
  86. University of Pennsylvania
  87. Regeneron Pharmaceuticals
  88. Neon Therapeutics
  89. Shanghai Fosun Pharmaceutical
  90. Karolinska University Hospital
  91. MedImmune
  92. Shanghai Jiao Tong University
  93. AO Foundation
  94. Paracelsus Medical University
  95. Ludwig Institute for Cancer Research
  96. dievini Hopp BioTech Holding
  97. Flagship Pioneering
  98. Life Sciences Partners
  99. Maryland Stem Cell Research Fund
  100. Morningside Group
  101. State Development & Investment
  102. University of Tokyo Edge Capital
  103. Abu Dhabi Investment Authority (ADIA)
  104. Atlas Venture
  105. Baillie Gifford
  106. Biomedical Advanced Research and Development Authority (BARDA)
  107. Defense Advanced Research Projects Agency (DARPA)
  108. European Investment Bank
  109. Fall Line Capital
  110. S2G Ventures
  111. Flanders Innovation & Entrepreneurship 
  112. Flu Lab
  113. High-Tech Gründerfonds (HTGF)
  114. Lapam Capital
  115. Lilly Asia Ventures
  116. MassChallenge
  117. MRL Ventures Fund
  118. Viking Global Investors
  119. OrbiMed Advisors
  120. Redmile Group
  121. Qiming Venture Partners
  122. Kreditanstalt für Wiederaufbau (KfW)
  123. Qatar Investment Authority (QIA)
  124. Temasek Holdings
  125. Baupost Group
  126. Y Combinator
  127. Terra Magnum Capital Partners
  128. Venture Challenge
  129. Zoic Capital 
  130. Bpifrance
  131. UNIIQ
  132. BB Biotech
  133. Boston Biotech Ventures
  134. Chartwave
  135. Colt Ventures
  136. Baird Capital
  137. Monsanto
  138. Boehringer Ingelheim Venture Fund
  139. Coppel Family
  140. Cormorant Asset Management
  141. Fund+
  142. Invus
  143. Macro Capital
  144. MPM Capital
  145. RA Capital Management
  146. Spinnotec
  147. Continental Grain Company (CGC)
  148. Julius Baer
  149. Redmile Group
  150. Omega Funds
  151. Wellington Management
  152. SIGMA Group
  153. ELMA Investments
  154. Fidelity Management
  155. Jiuyo Capital
  156. Blue I/O
  157. Boehringer Ingelheim Venture Fund
  158. Fang Fund Partners
  159. Hunt Technology Ventures
  160. MiraeAsset Financial Group
  161. Malaysian Life Sciences Capital Fund
  162. Rock Springs Capital
  163. Alexandria Venture Investments
  164. Brookside Capital
  165. Grand Decade
  166. Osage University Partners
  167. Longmen capital
  168. Platinum Asset Management
  169. Syngenta Ventures
  170. Tao Capital Partners
  171. Struengmann Family Office
  172. Healthcare Holdings
  173. Jebsen Capital
  174. Leerink Partners
  175. Pictet Group
  176. Steam Athena Capital
  177. Viking Global Investors
  178. Lewis & Clark AgriFood
  179. BVCF Management
  180. ArrowMark Partners
  181. BNP Paribas Fortis Private Equity
  182. Lupa Systems
  183. Novalis LifeSciences
  184. Yijing Capital
  185. Immatics
  186. Roche
  187. Novartis
  188. Regeneron Pharmaceuticals
  189. Seminis
  190. Ionis Pharmaceuticals
  191. 10x Genomics
  192. National Institute of Health
  193. Dana-Farber Cancer Institute
  194. Broad Institute
  195. Stanford University
  196. University of Texas
  197. Harvard University
  198. Massachusetts Institute of Technology
  199. University of California

Segmentation

The USD 10 billion (by 2021) financial opportunity within the mRNA Vaccines and Therapeutics market has been analysed across the following segments:

  • Type of Drug candidate
    • mRNA Vaccines
    • mRNA Therapies 
  • Analysis by Route of Administration
    • Intramuscular
    • Epicardial
    • Intradermal 
  • Analysis by Therapeutic Area
    • Infectious Diseases
    • Oncological Disorder
    • Cardiovascular Disorders
  • Analysis by Geography
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com